MimiVax is exploring new ways of stimulating immune response to fight cancer cells leveraging our proprietary survivin-targeting technology.

Product Candidate Indication Combination Preclinical Phase I Phase II Centers and Partners
SurVaxM Glioblastoma (GBM) Standard of Care
Potential for Orphan / Breakthrough Therapy Designation
Roswell Park Cancer Institute, Dana Farber Cancer Institute, Cleveland Clinic
SurVaxM Multiple Myeloma REVLIMID®
Roswell Park Cancer Institute, Celgene
SurVaxM Auto-immune Diseases TBD  
Anti-Survivin Monoclonal Antibody Cancers / Auto-immune Diseases TBD  
CAR-T-Sur Solid Tumors TBD
Sur-Dx Cancer TBD